BRAF Signaling and Targeted Therapies in Melanoma

被引：150

作者：

Dhomen, Nathalie ^{[1
]}

Marais, Richard ^{[1
]}

机构：

[1] Inst Canc Res, Sect Cell & Mol Biol, London SW3 6JB, England

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2009年 / 23卷 / 03期

关键词：

BRAF; Melanoma; MAPK signaling; Targeted therapies; Small molecule inhibitors; ONCOGENE-INDUCED SENESCENCE; REGULATED KINASE KINASE; ORAL MEK INHIBITOR; HOMOLOG B1 BRAF; CANCER-THERAPY; PHASE-II; CELLULAR SENESCENCE; ACQUIRED-RESISTANCE; AZD6244; ARRY-142886; MALIGNANT-MELANOMA;

D O I：

10.1016/j.hoc.2009.04.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The RAS/RAF/MEK/ERK signaling pathway has emerged as a major player in the induction and maintenance of melanoma, particularly the protein kinase BRAF, mutated in approximately 44% of melanoma cases. The availability of new drugs affecting the components of this pathway and pathways that may cooperate with MAPK signaling, means that targeted therapies are fast becoming a real option in the clinical management of melanoma. The authors discuss what they learned from clinical trials using first- and second-generation inhibitors to this pathway.

引用

页码：529 / +

页数：18

共 92 条

[1]

ADJEI AA, 2006, AACR NCI EORTC INT C

[2]

Adjei N.R.a.A., 2007, update on cancer therapeutics, V2, P111, DOI [DOI 10.1016/J.UCT.2007.10.001, 10.1016/j.uct.2007.10.001]

[3]

Agarwala S.S., 2007, J CLIN ONCOL, V25, P8510

[4]

Amaravadi R, 2007, J CLIN ONCOL, V25

[5]

[Anonymous], AACR NCI EORTC INT C

[6]

Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints [J].

Bartkova, Jirina ;

Rezaei, Nousin ;

Liontos, Michalis ;

Karakaidos, Panagiotis ;

Kletsas, Dimitris ;

Issaeva, Natalia ;

Vassiliou, Leandros-Vassilios F. ;

Kolettas, Evangelos ;

Niforou, Katerina ;

Zoumpourlis, Vassilis C. ;

Takaoka, Munenori ;

Nakagawa, Hiroshi ;

Tort, Frederic ;

Fugger, Kasper ;

Johansson, Fredrik ;

Sehested, Maxwell ;

Andersen, Claus L. ;

Dyrskjot, Lars ;

Orntoft, Torben ;

Lukas, Jiri ;

Kittas, Christos ;

Helleday, Thomas ;

Halazonetis, Thanos D. ;

Bartek, Jiri ;

Gorgoulis, Vassilis G. .

NATURE, 2006, 444 (7119) :633-637

[7]

Preclinical and clinical evaluation of farnesyltransferase inhibitors [J].

Charles Baum ;

Paul Kirschmeier .

Current Oncology Reports, 2003, 5 (2) :99-107

[8]

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma [J].

Bean, James ;

Riely, Gregory J. ;

Balak, Marissa ;

Marks, Jenifer L. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7519-7525

[9]

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group [J].

Bedikian, Agop Y. ;

Millward, Michael ;

Pehamberger, Hubert ;

Conry, Robert ;

Gore, Martin ;

Trefzer, Uwe ;

Pavlick, Anna C. ;

DeConti, Ronald ;

Hersh, Evan M. ;

Hersey, Peter ;

Kirkwood, John M. ;

Haluska, Frank G. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4738-4745

[10]

Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients [J].

Bianchini, Michele ;

De Brasi, Carlos ;

Gargallo, Patricia ;

Gonzalez, Mariana ;

Bengio, Raquel ;

Larripa, Irene .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (04) :292-300

← 1 2 3 4 5 6 7 8 9 10 →